| pubmed-article:2950769 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2950769 | lifeskim:mentions | umls-concept:C0034493 | lld:lifeskim |
| pubmed-article:2950769 | lifeskim:mentions | umls-concept:C0003765 | lld:lifeskim |
| pubmed-article:2950769 | lifeskim:mentions | umls-concept:C0020456 | lld:lifeskim |
| pubmed-article:2950769 | lifeskim:mentions | umls-concept:C0017725 | lld:lifeskim |
| pubmed-article:2950769 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2950769 | lifeskim:mentions | umls-concept:C0805586 | lld:lifeskim |
| pubmed-article:2950769 | pubmed:issue | 2 Pt 1 | lld:pubmed |
| pubmed-article:2950769 | pubmed:dateCreated | 1987-3-30 | lld:pubmed |
| pubmed-article:2950769 | pubmed:abstractText | The effects of beta-endorphin on glucose, insulin, and glucagon levels were studied in normal fasted adult male rabbits. An intravenous bolus of glucose (0.7 g/kg body wt) produced a hyperglycemic state (peak plasma glucose 306 +/- 22 mg/dl; means +/- SE) that lasted approximately 90 min. beta-Endorphin (31 micrograms/g body wt; iv) administered immediately prior to the glucose challenge resulted in plasma glucose levels that were significantly higher from 10 to 90 min after the glucose challenge (P less than 0.001-0.05). From 10 to 30 min, plasma insulin levels were significantly lower in the beta-endorphin group (P less than 0.001-0.05), peaking at one-half the control group levels. Glucagon levels were unchanged by the glucose bolus in either the control or beta-endorphin-treated group (means +/- SE = 102.8 +/- 4 pg/ml). In another experiment, a 30-min infusion of L-arginine (13 mg-1 X kg body wt-1 X min iv) in normal fasted rabbits produced a rapid (10 min) increase in plasma insulin and glucagon and a return to base-line levels 60 min after withdrawing the arginine stimulus. Plasma glucose levels were not altered by arginine (mean +/- SE = 94.5 +/- 1 mg/dl). Administration of beta-endorphin (31 micrograms/kg body wt iv) at the start of the arginine infusion resulted in a rapid (10 min) and long-lasting (up to 60 min) hyperglycemic effect associated with a significant decrease in insulin levels (10-20 min; P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:2950769 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2950769 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2950769 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2950769 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2950769 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2950769 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2950769 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2950769 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2950769 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2950769 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2950769 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2950769 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2950769 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2950769 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:2950769 | pubmed:issn | 0002-9513 | lld:pubmed |
| pubmed-article:2950769 | pubmed:author | pubmed-author:ChawlaR KRK | lld:pubmed |
| pubmed-article:2950769 | pubmed:author | pubmed-author:CollinsD CDC | lld:pubmed |
| pubmed-article:2950769 | pubmed:author | pubmed-author:Martino-Saltz... | lld:pubmed |
| pubmed-article:2950769 | pubmed:author | pubmed-author:SchleicherR... | lld:pubmed |
| pubmed-article:2950769 | pubmed:author | pubmed-author:CoanP APA | lld:pubmed |
| pubmed-article:2950769 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2950769 | pubmed:volume | 252 | lld:pubmed |
| pubmed-article:2950769 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2950769 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2950769 | pubmed:pagination | E255-9 | lld:pubmed |
| pubmed-article:2950769 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:meshHeading | pubmed-meshheading:2950769-... | lld:pubmed |
| pubmed-article:2950769 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:2950769 | pubmed:articleTitle | Beta-endorphin-induced hyperglycemia in rabbits: effects of a glucose or arginine challenge. | lld:pubmed |
| pubmed-article:2950769 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2950769 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
